NCT04582201View on ClinicalTrials.gov

Evaluate the Safety of agenT-797 in Participants With Moderate to Severe Difficulty Breathing Secondary to SARS-CoV-2

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

September 21, 2020

Primary Completion Date

April 23, 2023

Study Completion Date

April 23, 2023

Conditions
Respiratory Distress Syndrome, Adult
Interventions
DRUG

agenT-797

agenT-797 is an off-the-shelf cell therapy consisting of ≥ 95% allogeneic human unmodified iNKT cells isolated from 1 healthy donor mononuclear cell apheresis unit and expanded ex vivo.

Trial Locations (3)

10022

Weill Cornell Medicine New York Presbyterian, New York

40207

Norton Cancer Institute, St. Matthews Campus, Louisville

90404

Saint John's Cancer Institute, Santa Monica

Sponsors

Lead Sponsor

MiNK Therapeutics
All Listed Sponsors
lead

MiNK Therapeutics

INDUSTRY

NCT04582201 - Evaluate the Safety of agenT-797 in Participants With Moderate to Severe Difficulty Breathing Secondary to SARS-CoV-2 | Biotech Hunter | Biotech Hunter